Lipoprotein Nanoparticles for Diagnosis and Therapy 2.0
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Materials Science".
Deadline for manuscript submissions: closed (22 August 2022) | Viewed by 2660
Special Issue Editors
Interests: lipoprotein (structure, function, and metabolism); drug delivery; optimization of therapeutic payload delivery; lipoprotein mimetics; apolipoprotein mimetics; anticancer drugs
Special Issues, Collections and Topics in MDPI journals
Interests: fluorescence;biomedical and diagnostic fields; laser confocal microscopy; fluorescence resonance energy transfer (FRET); fluorescence lifetime imaging microscopy (FLIM); cellular imaging
Special Issue Information
Dear Colleagues,
Lipoprotein-based drug delivery has been pursued by several research groups since the 1980s. Nevertheless, despite its many advantages over existing technologies, no lipoprotein-based formulation appears close to being tested in clinical trials. Significant research efforts on rHDL are involved in atherosclerosis treatment. Moreover, synthetic lipoproteins (rHDL and rLDL) have been utilized in targeting various malignancies (e.g., cancer) of various tissues including, but not limited to adrenal, testes, ovary, liver, pancreas, breast, prostate, and brain in animal models. Moreover, owing to their inflammatory and antioxidant properties, these nanoparticles have become relevant in inflammatory diseases and those originating from oxidative stress. HDL and Apo-A1 are known to play a critical role in immunity as well. Several reports have implicated rHDL nanoparticles in the therapy of neurodegenerative diseases such as Alzheimer’s. Considering the wide array of applications of these mimics of endogenous HDL, this Special Edition titled “Lipoprotein Nanoparticles for Diagnosis and Therapy” of the International Journal of Molecular Sciences is intended to explore the paths for overcoming the current barriers to the delivery of anticancer agents using reconstituted HDL or HDL mimetics by reporting on the latest developments by the leading research groups in this area.
Prof. Andras G. Lacko PhD.
Asst. Prof. Rafal Fudala PhD
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Recent advances in HDL and HDL mimetic nanoparticles
- Tumor selective delivery
- Tumor imaging
- Specific therapeutic applications
- Challenges to overcome for translation
- HDL and antioxidant propertie
- Apolipoproteins and inflammatory properties
- Tumor microenvironment
